Rossby Financial
LCTX icon

Rossby Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Rossby Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$55 Hold
58
– – ﹤0.01% 2456
2026
Q2 		$76 Hold
58
– – ﹤0.01% 2133
2026
Q1 		$92 Hold
58
– – ﹤0.01% 2248
2025
Q4 		$97 Hold
58
– – ﹤0.01% 1791
2025
Q3 		$98 Hold
58
– – ﹤0.01% 1457
2025
Q2 		$53 Hold
58
– – ﹤0.01% 1234
2025
Q1 		$28 Buy
+58
New +$34 ﹤0.01% 1072

Other funds holding LCTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Defender Capital
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Rossby Financial's LCTX Position: Q3 2026 in Review

Rossby Financial held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 58 shares worth $55. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

Rossby Financial first reported a position in LCTX in Q1 2025 and has held it in 7 quarters since. The position peaked at $98 in Q3 2025. 109 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Rossby Financial held 58 shares of Lineage Cell Therapeutics worth $55 as of Q3 2026.
  • Rossby Financial left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Rossby Financial's portfolio in Q3 2026, its #2456 holding.
  • Rossby Financial first reported a position in Lineage Cell Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Rossby Financial's Lineage Cell Therapeutics position peaked at $98 in Q3 2025.
  • 109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Rossby Financial's 13F filing for Q3 2026, filed 5 Nov 2026.